Epidermal-type FABP is a predictive marker of clinical response to systemic treatment and ultraviolet therapy in psoriatic skin lesions

Miyake, Takahiro; Ogawa, Emiko; Mikoshiba, Asuka; Kobayashi, Akihiro; Hosoe, Hiroaki; Kashiwabara, Shoji; Uhara, Hisashi; Owada, Yuji; Okuyama, Ryuhei

doi:10.1016/j.jdermsci.2012.09.002

Cited by 14 publications

(33 citation statements)

References 10 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They found a decrease in the concentration of the protein under study after treatment and suggested that FABP-5 could be used as a marker for monitoring the efficacy of treatment. The study group, however, was very small -just 7 patients (2 treated with adalimumab, 3 with infliximab, 2 with NB-UVB), which is why the findings and conclusions of the study must be viewed as rather hypothetical [20]. racji oraz upośledzać funkcję błony podstawnej [11].…”

Section: Lipidy W Naskórkumentioning

confidence: 99%

“…E-FABP is also known as psoriasis-associated FABP (PA-FABP), which reflects its proven link to this dermatosis. A significantly increased expression of E-FABP has been demonstrated in psoriatic lesions [19,20]. The concentration of this protein in skin specimens failed to correlate with Psoriasis Area and Severity Index (PASI), however it exhibited a correlation with the severity of erythema, infiltration and scaling evaluated as PASI components [19].…”

Section: Lipidy W Naskórkumentioning

confidence: 99%

“…E-FABP jest nazywane również białkiem związanym z łuszczycą (psoriasis-associated FABP -PA-FABP), co podkreśla już udowodnione powiązania z tą dermatozą. Wykazano istotnie zwiększoną ekspresję E-FABP w zmianach łuszczycowych [19,20]. Stężenie tego białka w wycinkach skórnych nie korelowało z PASI (Psoriasis Area and Severity Index), natomiast korelowało z nasileniem rumienia, nacieku i łuski, ocenianych jako składowe skali PASI [19].…”

Section: Lipidy W Naskórkuunclassified

“…Stwierdzili zmniejszone stężenia badanego białka po leczeniu i sugerowali, że FABP-5 może być markerem służącym do monitorowania efektywności terapii. Grupa badana była jednak bardzo nieliczna -7 pacjentów (2 leczonych adalimumabem, 3 infliksymabem, 2 NB-UVB), co powoduje, że wyniki i wnioski są raczej hipotetyczne [20].…”

Section: Lipidy W Naskórkuunclassified

“…Miyake i wsp. nie wykazali różnicy w stężeniach FABP5 między grupą badaną i kontrolną, mimo zwiększonej ekspresji w zmianach łuszczycowych [20].…”

Section: Kwasy Tłuszczoweunclassified

See 4 more Smart Citations

The role of lipids in psoriasis

Baran¹,

Kiluk²,

Myśliwiec³

et al. 2017

View full text Add to dashboard Cite

Psoriasis, affecting 2-4% of the world's population, is a chronic recurrent inflammatory skin disease. Its multifactorial aetiopathogenesis consists of, for example, abnormal epidermal proliferation, immune disturbances, and genetic, psychosomatic, environmental and hormonal factors. Psoriasis is also considered to be a systemic disorder closely associated with cardiovascular diseases, atherosclerosis, diabetes mellitus, obesity or metabolic syndrome. Lipids have a variety of biological functions. They participate not only in energy storage and expenditure or the formation of cell membranes, but also in inflammatory and metabolic signalling pathways. Disturbances in their homeostasis lead to the development of immunometabolic disorders, including psoriasis. Based on the available literature, this article presents selected molecular and clinical aspects involved in the multidirectional effect of lipids on psoriasis.streszczenie Łuszczyca, która występuje u 2-4% populacji na świecie, jest przewlekłą i nawrotową chorobą zapalną skóry. Na jej wieloczynnikową etiopatogenezę składają się m.in. nieprawidłowa proliferacja naskórka, zaburzenia immunologiczne, czynniki genetyczne, psychosomatyczne, środowiskowe i hormonalne. Łuszczyca jest również uznawana za schorzenie ogólnoustrojowe, związane z chorobami układu sercowo--naczyniowego, miażdżycą, cukrzycą, otyłością i zespołem metabolicznym. Lipidy pełnią wiele biologicznych funkcji, biorą udział nie tylko w magazynowaniu i wydatkowaniu energii, tworzeniu błon komórko-wych, lecz także w zapalnych i metabolicznych szlakach sygnałowych. Zaburzenia ich homeostazy powodują rozwój schorzeń immunometabolicznych, w tym łuszczycy. W niniejszej pracy przedstawiono na podstawie dostępnego piśmiennictwa wybrane aspekty molekularne i kliniczne wielokierunkowego wpływu lipidów na łuszczycę.

show abstract

Section: Lipidy W Naskórkumentioning

confidence: 99%

Section: Lipidy W Naskórkumentioning

confidence: 99%

Section: Lipidy W Naskórkuunclassified

“…Miyake i wsp. nie wykazali różnicy w stężeniach FABP5 między grupą badaną i kontrolną, mimo zwiększonej ekspresji w zmianach łuszczycowych [20].…”

Section: Kwasy Tłuszczoweunclassified

See 3 more Smart Citations

The role of lipids in psoriasis

Baran¹,

Kiluk²,

Myśliwiec³

et al. 2017

View full text Add to dashboard Cite

show abstract

Adipocyte Fatty Acid‐Binding Protein as a Novel Marker of Psoriasis and Clinical Response to Acitretin

Baran

Kiluk

Świderska

et al. 2019

Lipids

View full text Add to dashboard Cite

Psoriasis is a systemic disease associated with metabolic syndrome and cardiometabolic diseases. Adipocyte fatty acid‐binding protein (A‐FABP, FABP4) is a relevant mediator of lipid metabolism and several comorbidities development. Aim of the study was to explore the possible role of FABP4 in psoriasis and assess its relationship with disease activity, inflammation or metabolic disturbances, and impact of systemic treatment. Fasting blood samples were obtained from 33 patients with active plaque‐type psoriasis before and after 12 weeks of therapy and from 11 healthy volunteers. Serum FABP4 concentrations were analyzed by the enzyme‐linked immunosorbent assay (ELISA) and statistically analyzed for their correlations with clinical outcomes and the treatment introduced. Serum FABP4 levels were significantly increased in psoriatics compared to controls (p = 0.03). No relationship between the protein and psoriasis severity expressed through psoriasis area and severity index (PASI) was noted (p = 0.57). FABP4 did not correlate with CRP (p = 0.41), lipid profile, and body mass index (BMI) nor the glucose level or liver enzyme activity. FABP4 significantly correlated with morphotic blood elements. After total therapy, FABP4 did not statistically change (p = 0.07), but significantly decreased after administering acitretin (p = 0.03). FABP4 is a potential marker of psoriasis and clinical outcome after therapy with acitretin. Adipocyte‐type FABP may be related to hematological disorders or obesity‐mediated comorbidities in psoriasis.

show abstract

Liver fatty acid-binding protein might be a predictive marker of clinical response to systemic treatment in psoriasis

et al. 2019

View full text Add to dashboard Cite

Fatty acid-binding proteins play an inconclusive role in lipid metabolism and cardiometabolic diseases (CMDs) which are closely related with psoriasis. Aim of the study was to investigate the diagnostic value of serum liver fatty acid-binding protein (FABP1) level and associations with disease severity, inflammation or metabolic parameters and influence of systemic treatment in psoriatic patients. The study included thirty-three patients with active plaque-type psoriasis and eleven healthy volunteers. Blood samples were obtained before and after 12 weeks of therapy with methotrexate and acitretin. Serum FABP1 concentrations were analyzed by the enzyme-linked immunosorbent assay. Statistical analysis was performed for correlation of FABP1 with anthropometric, metabolic or inflammatory indices and treatment used. Serum liver-type FABP levels were significantly increased in psoriatic patients compared to the controls ( p < 0.001). No statistical correlations between FABP1 and PASI ( p = 0.25) was noted, however patients with severe psoriasis had the highest level of FABP1. No significance with metabolic parameters was obtained, beside a positive significant relation with BMI after therapy ( p = 0.03). Liver-type FABP significantly correlated with CRP ( p = 0.01) and morphotic blood elements. Systemic treatment combined resulted in significant decrease of FABP1 ( p = 0.04), regardless of the drug: p = 0.1 in acitretin group, p = 0.3 in methotrexate group. Liver-type FABP might be a novel marker of psoriasis and predictor of clinical response to systemic therapy. FABP1 could be involved in CMDs risk assessment and perhaps link psoriasis with hematological disorders.

show abstract

Epidermal-type FABP is a predictive marker of clinical response to systemic treatment and ultraviolet therapy in psoriatic skin lesions

Cited by 14 publications

References 10 publications

The role of lipids in psoriasis

The role of lipids in psoriasis

Adipocyte Fatty Acid‐Binding Protein as a Novel Marker of Psoriasis and Clinical Response to Acitretin

Liver fatty acid-binding protein might be a predictive marker of clinical response to systemic treatment in psoriasis

Contact Info

Product

Resources

About